Standardization of C-Peptide and HbA1C Measurements Program
Standardization of C-Peptide and HbA1C Measurements Program
批准号:
10662554
负责人:
Randie Little
金额:
$47.74万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-15 至 2027-05-31
关键词:
AffectAmericanBeta CellBiologicalBiological AssayBlood GlucoseBlood VesselsBlood specimenC-PeptideCalibrationCapillary ElectrophoresisCaringCell physiologyCertificationChronicChronic DiseaseClinicalClinical ChemistryClinical ResearchComplications of Diabetes MellitusDataData AnalysesDevelopmentDiabetes MellitusDiagnosisDiagnosticDiseaseDisease ProgressionEvaluationEyeFosteringFreezingGlycosylated hemoglobin AGoalsHeartHemoglobinHyperglycemiaInsulin deficiencyInsulin-Dependent Diabetes MellitusInternationalKidneyLaboratoriesManufacturerMeasurementMethodsMonitorPathologistPerformancePeripheral NervesPersonsPublishingRecommendationReportingResearchResearch Project GrantsRiskSchemeSiteSpecific qualifier valueSpecificityStandardizationTestingTherapeutic InterventionUnited States National Institutes of HealthUpdateVariantWhole Bloodcollegediabetes controldiagnostic tooleffectiveness evaluationglycemic controlhigh riskimprovedmeetingsmemberpreservationprogramsweb site
中文摘要
项目总结
英文摘要
Project Summary
Diabetes mellitus is a chronic disorder characterized by insulin deficiency,
hyperglycemia and high risk for development of complications of the eyes, kidneys,
peripheral nerves, heart and blood vessels. The disease is highly prevalent,
affecting more than 30 million people in the U.S. Monitoring of glycemic control
has traditionally been considered a cornerstone of diabetes care. The importance
of monitoring glycemia has been established by studies proving a direct
relationship between mean blood glucose and the development and progression of
the chronic complications of diabetes. The landmark Diabetes Control and
Complications Trial (DCCT), completed in 1993, showed that risks for development
and/or progression of the chronic complications of type 1 diabetes is closely
related to the degree of glycemic control, as assessed by HbA1c determinations.
The importance of HbA1c as a marker of glycemic control in diabetes mellitus, and
more recently as a diagnostic tool, is now well established. This proposed project
will improve the measurement of HbA1c for optimal clinical and diagnostic use.
This will be done through an established standardization program by continuously
tightening criteria for method and laboratory certification, monitoring performance
of laboratory methods and laboratories, and testing and publishing data on HbA1c
analytical and biological interferences.
Preservation of beta cell function in type 1 diabetes has been identified as an
important goal in delaying progression of the disease at onset and also for
therapeutic intervention. Accurate, standardized measurement of C-peptide will
aid in this goal and is also the subject of this proposal. Standardization will be
accomplished by implementation of a traceability scheme with re-calibration of C-
peptide methods by each manufacturer and monitoring the effects of re-calibration
by evaluation of proficiency testing data. In addition, criteria will be formulated for
acceptable accuracy, precision and specificity of C-peptide assays.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Standardization of C-Peptide and HbA1c Measurements Program
-
批准号:9389632
-
项目类别:
-
资助金额:$174.38万
-
财政年份:2012
-
负责人:Randie Little
-
依托单位:
Standardization of C-Peptide and HbA1C (UC4)
-
批准号:8386855
-
项目类别:
-
资助金额:$217.26万
-
财政年份:2012
-
负责人:Randie Little
-
依托单位:
海外基金